Plasma factor vila: Measurement and potential clinical significance

Pathophysiology of Haemostasis and Thrombosis

Volumn 26, Issue , 1996, Pages 66-71

  Morrissey, James H ^a  

^a OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

Author keywords

Factor VII; Factor VIla; Heart disease; Plasma; Risk factors; Thromboplastin; Thrombosis; Tissue factor

Indexed keywords

BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 7A; THROMBOPLASTIN;

ASSAY; BLOOD CLOTTING; BLOOD LEVEL; CONFERENCE PAPER; HEART DISEASE; HUMAN; PRIORITY JOURNAL; RISK FACTOR; THROMBOSIS;

CARDIOVASCULAR DISEASES; FACTOR VIIA; HUMANS; PREDICTIVE VALUE OF TESTS; RISK FACTORS; THROMBOSIS;

EID: 0029928681     PISSN: 14248832     EISSN: 14248840     Source Type: Journal    
DOI: 10.1159/000217243     Document Type: Article

References (50)

1. Seligsohn U. Kasper CK, Osterud B. Rapaport SI: Activated factor VII: Presence in factor IX concentrate and persistence in the circulation after infusion. Blood 1978:53:828.
2. Miller BC, Hultin MB, Jesty J: Altered factor VII activity in hemophilia. Blood 1985,65:845.
3. Nakagaki T. Foster DC. Berkner KL, Kisicl W: Initiation of the extrinsic pathway of blood coagulation: Evidence for the tissue factor dependent autoactivation of human coagulation factor VII. Biochemistry 1991;30:10819-10824.
4. Neuenschwander PF, Morrissey JH: Deletion of the membrane-anchoring region of tissue factor abolishes autoactivation of factor VII. but not cofactor function: Analysis of a mutant with a selective deficiency in activity. J Biol Chcrn 1992:267: 14477-14482.
5. Rapaport SI: Regulation of the tissue factor pathway. Ann NY Acad Sci 1991:614:151.
6. Meade TW. Mellows S, Brozovic M. Miller GJ, Chakrabarti RR, North WRS. Haines AP. Stirling Y, Ime-son JD, Thompson SG: Haemostatic function and ischaemic heart disease: Principal results of the North-wick Park Heart Study. Lancet 1986;vol ii:533-537.
7. Morrissey JH, Macik BG: Novel clotting assay for factor Vila in plasma using a tissue factor mutant that does not support activation of factor VII (abstract). Arteriosclcr Thromb 1991:1 L1544A.
8. Morrissey JH. Macik BG. Neuenschwander PF, Comp PC: Quantitation of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation. Blood 1993;81:734-744.
9. Wildgoosc P, Nemerson Y. Hansen LI. Nielsen FE, Glazer S. Hcdner U: Measurement of basal levels of factor Vila in hemophilia A and B patients. Blood 1992:80:25-28.
10. Kario K. Miyata T. Sakata T. Matsuo T. Kato H: Fluorogenic assay of activated factor VII. Plasma factor Vila levels in relation to arterial cardiovascular diseases in Japanese. Arteriscler Thromb 1994:14:265-274.
11. Osterud B. Berre A, Otnaess B-A. Bjoerklid E. Prydz H: Activation of the coagulation factor VII by tissue thromboplastin and calcium. Biochemistry 1972:11:2853.
12. Dalakcr K. Prydz H: The coagulation factor VII in pregnancy. Br J Haematol 1984;56:233-241.
13. Hayes TE. Pike J. Tracy RP: Factor VII assays. Arch Pathol lab Med 1993:177:52-57.
14. Hubbard AR, Parr LJ: Phospholipase C mediated inhibition of factor VII requires triglyceride-rich lipoproteins. Thromb Res 1991:62:335-344.
15. Kitchen S. Malia RG. Preston FE: A comparison of methods for the measurement of activated factor VII. Thromb Haemost 1992:68:301-305.
16. Seligsohn U. Osterud B. Rapaport SI: Coupled amidolytic assay for factor VII: Its use with a clotting assay to determine the activity state of factor VII. Blood 1978:52:978-988.
17. Hemker HC, Muller AD, Gonggrup R: The estimation of activated human blood coagulation factor VII. J Mol Med 1976;1:127-134.
18. van Dcijk WA. van Dam-Mieras MCE, Muller AD, Hemker HC: Evaluation of a coagulation assay determining the activity state of factor VII in plasma. Haemostasis 1983;13:192-197.
19. Kitchen S, Malia RG, Greaves M. Preston FE: A method for the determination of activated factor VII using bovine and rabbit brain thromboplastins: Demonstration of increased levels in disseminated intravascular coagulation. Thromb Res 1988;50:191-200.
20. Poggio M, Tripodi A, Mariani G. Mannucci PM: Factor VII clotting assay: Influence of different thromboplastins and factor VH-deficient plasma. Thromb Haemost 1991:65: 160-164.
21. Kario K. Matsuo T, Asada R. Sakata T. Kato H. Miyata T: The strong positive correlation between factor VII clotting activity using bovine thromboplastin and the activated factor VII level. Thromb Haemost 1995:73:429-434.
22. Hultin MB: Fibrinogen and factor VII as risk factors in vascular disease. Prog Hcmost Thromb 1991: 10:215-241.
23. Mann KG: Factor VII assays, plasma triglyceride levels, and cardiovascular disease risk. Arteriosclerosis 1989:9:783-784.
24. Miller GJ, Stirling Y. Esnouf MP, Heinrich J, van dc Loo J. Kienast J, Wu KK, Morrissey JH. Meade TW. Martin JC. Imeson JD. Cooper JA, Finch A: Factor VIl-deficieM substrate plasmas depleted of protein C raise the sensitivity of the factor VII bio-assay to activated factor VII: An international study. Thromb Haemost 1994:71:38-48.
25. Fiore MM, Ncuenschwander PF. Morrissey JH: The biochemical basis for the apparent defect of soluble mutant tissue factor in enhancing the proteolytic activities of factor Vila. J Biol Chem 1994:269:143-149.
26. Hubbard AR, Barrowcliffc TW: Measurement of activated factor VII using soluble mutant tissue factor-Proposal for standardization. Thromb Haemost 1994:72:643-651.
27. Raskob GE, Durica SS, Morrissey JH. Owen WL, Comp PC: Effect of treatment with low-dose warfarin-aspirin on activated factor VII. Blood 1995;85:3034-3039.
28. Sakata T. Kario K, Matsuo T, Ka-tavama Y, Matsuyama T. Kato H, Miyata T: Suppression of plasma-activated factor VII levels by warfarin therapy. Arteriscler Thromb 1995;15:241-246.
29. Moor E. Silveira A, van’t Hooft F, Suontaka AM. Eriksson P. Blom-back M. Hamsten A: Coagulation factor VII mass and activity in young men with myocardial infarction at a young age: Role of plasma lipoproteins and factor VII genotype. Arterioscier Thromb 1995:15: 655-664.
30. Limentani SA, Gowell KP. Deitchcr SR: In vitro characterization of high purity factor IX concentrates for the treatment of hemophilia B. Thromb Haemost 1995;73:584-491.
31. Berthier A, Pommereuil M. Coat-melcc B, Guerct P. Bara L. Fauchet R. Samama MM: Direct measurement and kinetic study of activated FVII in hemophiliacs after FVIIa infusion (abstract). Thromb Haemost 1995,73:1187.
32. Balleiscn L. Schulte H, Assmann G. Epping P-H. van de Loo J: Coagulation factors and the progress of coronary heart disease. Lancet 1987:vol ii: 461.
33. Broadhurst P. Kelleher C, Hughes L. Imeson JD. Raftcry EB: Fibrinogen factor VII clotting activity and coronary artery disease severity. Atherosclerosis 1990:85:169-173.
34. Carvalho de Sousa J. Azevedo J. Soria C. Barros F. Ribeiro C. Parreira F, Caen JP: Factor VII hyperactivity in acute myocardial thrombosis. A relation to the coagulation activation. Thromb Res 1988:51:165-173.
35. Cortellaro M, Boschetti C. Cofran-cesco E. Zanussi C, Catalano M. dc Gaetano G, Gabriclli L. Lombardi B. Spccchia G. Tavazzi L, Tremoli E, della Volpe A, Polli E, the PLAT Study Group: The PLAT Study: Hemostatic function in relation to atherothrombotic ischemic events in vascular disease patients: Principal results. Arterioscier Thromb 1992:12:1063-1070.
36. Heinrich J. Balleisen L, Schulte H. Assmann G, van de Loo J: Fibrinogen and factor VII in the prediction of coronary' risk-Results from the PROCAM study in healthy men. Ar-teriosclcr Thromb 1994:14:54-59.
37. Hoffman C. Shah A, Sodums M, Hultin MB: Factor Vll activity state in coronary artery disease. J Lab Clin Med 1988:111:475-481.
38. Hoffman CJ, Miller RH, Lawson WE, Hultin MB: Elevation of factor VII activity and mass in young adults at risk of ischemic heart disease. J Am Coll Cardiol 1989:14: 941-946.
39. Kario K. Sakata T. Matsuo T, Miya-ta T: Factor VII in non-insulin-de-pendent diabetic patients with microalbuminuria. Lancet 1993:342: 1552.
40. Kario K. Matsuo T. Matsuo M. Masanobu K, Yamada T. Nakamura S. Sakata T. Kato H. Miyata T: Marked increase of activated factor VII in uremic patients. Thromb Haemost 1995:73:763-767.
41. Orlando M, Leri O, Macioce G, Mattia G, Ferri GM: Factor VII in subjects at risk for thromboembolism: Activation or increased synthesis? Haemostasis 1987:17:340-343.
42. Ruddock V. Meade TW: Factor VII activity and ischaemic heart disease: Fatal and non-fatal events. Q J Med 1994:87:403-406.
43. Suzuki T, Yamauchi K. Matsushita T, Furumichi T, Furui H, Tsuzuki J, Saito H: Elevation of factor VII activity and mass in coronary artery disease of varying severity. Clin Cardiol 1991:14:731-736.
44. ARIC Investigators: The atherosclerosis risk in communities (ARIC) study: Design and Objectives. Am J Epidemiol 1989:129:687-702.
45. Bara L, Nicaud V. Tiret L, Cambien F. Samama MM. on behalf of the EARS group: Expression of a paternal history of premature myocardial infarction on fibrinogen, factor VIIC and PAI-1 in European offspring-The EARS study. Thromb Haemost 1994,71:434-440.
46. Koster T. Rosendaal FR. Reitsma PH. van der Velden PA. Briet E, Vandenbroucke JP: Factor VII and fibrinogen levels as risk factors for venous thrombosis. Thromb Haemost 1994:71:719-722.
47. Sosef MN. Bosch JG, van Oostayen J. Visser T. Rciber JHC, Rosendaal FR: Relation of plasma coagulation factor VII and fibrinogen to carotid artery intima-media thickness. Thromb Haemost 1994:72:250-254.
48. Vaziri ND. Kennedy SC. Kennedy D. Gonzales E: Coagulation, fibrinolytic. and inhibitory proteins in acute myocardial infarction and angina pectoris. Am J Med 1992;93: 651-657.
49. Folsom AR. Wu KK, Shahar E. Davis CE: Association of hemostatic-variables with prevalent cardiovascular disease and asymptomatic carotid artery atherosclerosis. Artc-rioscler Thromb 1993; 13:1829-1836.
50. Bauer KA: laboratory markers of coagulation activation. Arch Pathol Lab Med 1993;117:71-77.